Human Flt3 ligand from Pichia pastoris inhibits growth of lymphoma and colon adenocarcinoma in mice

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 3, 2006, Pages 161-166

  Zhang, Yan Li ^a   Wei, Yi Ju ^a   Deng, Yan Chun ^a   Wang, Ya Dong ^a   Liu, Chang Zheng ^a   Su, Lin ^a   Yang, Ke Gong ^a   Chen, Song Sen ^a,b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NONE   (China)

Author keywords

Antitumor; C26 colon adenocarcinoma; Cytokine; EL 4 lymphoma; Flt3 ligand

Indexed keywords

CYTOKINE; FLT3 LIGAND; RECOMBINANT HUMAN FLT3 LIGAND; UNCLASSIFIED DRUG; FLT3 LIGAND PROTEIN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CHO CELL; COLON ADENOCARCINOMA; CONTROLLED STUDY; GROWTH INHIBITION; LYMPHOMA; MALE; MOUSE; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; COLON TUMOR; IMMUNOTHERAPY; PATHOLOGY; PICHIA;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; COLONIC NEOPLASMS; IMMUNOTHERAPY; LYMPHOMA; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PICHIA;

EID: 33646691036     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.comppsych.2005.08.001     Document Type: Article

References (20)

1. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FA, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75:1157-67, 1993.
2. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 23:1121-1129, 1995.
3. Maraskovsky E, Pulendran B, Brasel K, Teepe M, Roux ER, Shortman K, Lyman SD, McKenna HJ. Dramatic numerical increase of functionally mature dendritic cells in hFLT3 ligand-treated mice. Adv Exp Med Biol 417:33-40, 1997.
4. Reber AJ, Ashour AE, Robinson SN, Talmadge JE, Solheim JC. Flt3 ligand bioactivity and pharmacology in neoplasia. Curr Drug Targets Immune Endocr Metabol Disord 4:149-56, 2004.
5. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625-631, 1997.
6. Lynch DH. Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit Rev Immunol 18:99-107, 1998.
7. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer-Res 58:380-383, 1998.
8. Silver D F, Hempling R E, Piver M S, Repasky EA. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol-Oncol 77:377-82, 2000.
9. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. hFLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 161:6164-70, 1998.
10. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511-3516, 1997
11. Braun SE Chen K, Blazar BR, Orchard PJ, Sledge G, Robertson MJ, Broxmeyer HE. Cornetta K. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther 10:2141-51, 1999.
12. Wang A, Braun S E, Sonpavde G, Cornetta K. Antileukemic activity of Flt3 ligand in murine leukemia. Cancer-Res 60: 1895-900, 2000.
13. Alsheikhly AR, Zweiri J, Walmesley AJ, Watson AJ, Christmas SE. Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model. Cancer Immunol Immunother 53:946-54, 2004.
14. Wang H, Dai J, Hou S, Qian W, Li B, Ma J, Fan X, Zhao J, Yang S, Sang H, Yang Q, Wang R, Guo Y. Treatment of hepatocellular carcinoma with adenoviral vector-medialed Flt3 ligand gene therapy. Cancer Gene Ther 12:769-77, 2005.
15. Averbook BJ, Schuh JL, Papay R, Maliszewski C. Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother 25:27-35, 2002.
16. Ciavarra RP, Somers KD, Brown RR, Glass WF, Consolvo PJ, Wright GL, Schellhammer PF. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer-Res 60:2081-4, 2000.
17. Favre FN, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F, Bonnette B. Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int-J-Cancer 86: 827-34, 2000.
18. Zhang YL, Chen SS, Yang KG, Su L, Deng YC, Liu CZ. Functional expression, purification, and characterization of human Flt3 ligand in the Pichia pastoris system. Protein Expr Purif 42:246-54, 2005.
19. Wodnar-Filipowicz A. Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci 18:247-51, 2003.
20. Corbett TH, DP Griswold Jr, Roberts BJ, Peckham JC, and Schabel FM. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res 35: 2434-2437, 1975.